June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Evaluation of suprachoroidal CLS-TA and oral prednisone in a porcine model of uveitis
Author Affiliations & Notes
  • Glenn Noronha
    R&D, Clearside Biomedical, Inc, Atlanta, GA
  • Kristin Blackwell
    R&D, Clearside Biomedical, Inc, Atlanta, GA
  • Brian C Gilger
    Department of Clinical Sciences, North Carolina State University, Raleigh, NC
  • Jennifer Kissner
    R&D, Clearside Biomedical, Inc, Atlanta, GA
  • Samirkumar Rajnikant Patel
    R&D, Clearside Biomedical, Inc, Atlanta, GA
  • Kaitlyn T Walsh
    Department of Clinical Sciences, North Carolina State University, Raleigh, NC
  • Footnotes
    Commercial Relationships Glenn Noronha, Clearside Biomedical, Inc (E); Kristin Blackwell, Clearside Biomedical, Inc (E); Brian Gilger, None; Jennifer Kissner, Clearside Biomedical, Inc (E); Samirkumar Patel, Clearside Biomedical, Inc (E); Kaitlyn Walsh, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3110. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Glenn Noronha, Kristin Blackwell, Brian C Gilger, Jennifer Kissner, Samirkumar Rajnikant Patel, Kaitlyn T Walsh; Evaluation of suprachoroidal CLS-TA and oral prednisone in a porcine model of uveitis. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3110.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To compare the anti-inflammatory effects of a suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension with clinically relevant doses of oral prednisone in a porcine model of acute uveitis.

Methods: Twenty-four hours after the induction of acute posterior uveitis by intraocular lipopolysaccharide (LPS) injection (Day 0) into the vitreous, 50 µL of balanced salt solution (BSS, Group 1) or CLS-TA (2 mg, Group 3) was injected into the suprachoroidal space (SCS). In Groups 2 and 4, oral prednisone (1 mg/kg/day, Group 2 or 0.1 mg/kg/day, Group 4) was dosed on Day 0, and repeated every 24 hours until euthanasia on day 3. The doses chosen for this study reflect the doses typically used to treat patients with uveitis, for initial dose (1 mg/kg/day) and maintenance dose (0.1 mg/kg/day). Only the right eye of each animal was used in the study and the left eye was unaltered (n=4/group). Eyes were examined daily, which included measuring inflammation scores (modified Hackett-McDonald) and intraocular pressure (IOP). Safety assessments and histopathology were performed on all eyes.

Results: Following induction with LPS, mean inflammation scores for all groups increased significantly compared with pre-induction scores. After treatment, mean inflammation scores decreased in all groups. On Days 1 and 2 only, Group 3 (suprachoroidal CLS-TA) had mean cumulative inflammation scores significantly lower than Group 1 (p≤0.04), the BSS, or untreated control group. By day 3, Group 2 (high dose oral prednisone) and Group 3 (CLS-TA) had significantly lower mean cumulative inflammation scores than Group 1 (BSS) treated eyes (p<0.034). In Group 4 (low dose oral prednisone), mean cumulative inflammation scores were not significantly different than BSS treated eyes at any treatment time (p>0.05). Mean histologic inflammation scores of the anterior and posterior segment with CLS-TA (Group 3) were significantly lower than eyes treated with BSS (Group 1).

Conclusions: These results suggest that suprachoroidal injection of CLS-TA resulted in more rapid anti-inflammatory effect than oral prednisone (Day 1 vs Day 3), was as effective as high dose oral prednisone (Day 3), and was superior to low dose prednisone in its anti-inflammatory effect in this porcine model of acute uveitis.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×